Search

Your search keyword '"Lalloo F."' showing total 40 results

Search Constraints

Start Over You searched for: Author "Lalloo F." Remove constraint Author: "Lalloo F." Topic breast cancer Remove constraint Topic: breast cancer
40 results on '"Lalloo F."'

Search Results

1. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions

2. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies

9. A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers

10. Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers

11. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

12. Young age at first pregnancy does protect against early onset breast cancer in <italic>BRCA1</italic> and <italic>BRCA2</italic> mutation carriers.

13. Association of PHB 1630 C > T and MTHFR 677 C > T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study

14. Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers

15. ENIGMA - Evidence-based Network for the Interpretation of Germline Mutant Alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes

16. Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2

17. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers

18. Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer

19. Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers

20. Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction

21. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)

22. Is multiple SNP testing in BRCA2 and BRCA1 female carriers ready for use in clinical practice? Results from a large Genetic Centre in the UK.

23. Familial Breast Cancer.

24. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT.

25. Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status.

26. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.

27. Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and: implications for screening.

28. Inherited association of breast and colorectal cancer: limited role of CHEK2 compared with high-penetrance genes.

29. Surgical decisions made by 158 women with hereditary breast cancer aged <50 years.

30. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme.

31. Low rate of TP53 germline mutations in breast cancer/sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome.

32. Risk assessment and management of high risk familial breast cancer.

33. Exploring the link between MORF4L1 and risk of breast cancer

34. Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer

35. Uptake of screening and prevention in women at very high risk of breast cancer.

36. Risk of breast cancer in male BRCA2 carriers.

37. Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes.

38. Guidelines for Follow-Up of Women at High Risk for Inherited Breast Cancer: Consensus Statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer.

39. Management of Hereditary Breast Cancer.

40. Mutation-Specific Survival of Inherited Breast Cancer.

Catalog

Books, media, physical & digital resources